Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

‘Weak’ evidence leads to NICE no for three leukaemia drugs

May 6, 2011
Sales and Marketing Glivec, NICE, Sprycel, Tasigna

NICE has not recommended three major drugs for the rare blood cancer chronic myeloid leukaemia. In draft guidance on treating …

News
Caribbean tunicate Ecteinascidia turbinata

NICE gives final no to PharmaMar’s Yondelis

April 27, 2011
Sales and Marketing NICE, PharmaMar, Yondelis, ovarian cancer

A lack of evidence and an unconvincing patient access scheme has seen PharmaMar fail to win NICE backing for its …

News
Novartis' Afinitor (everolimus)

NICE unimpressed with Novartis’ patient access scheme

April 19, 2011
Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis

Novartis has been dealt a blow by NICE after the cost-effectiveness body finally refused to recommend, on appeal, its kidney …

News
GP prescribing

GPs asked to squeeze drugs bill

April 14, 2011
Sales and Marketing AZ, GPs, NHS, NICE, prescribing

GPs are being asked not to prescribe NICE-approved drugs in order to cut costs.In the last year more than half …

News
Yondelis - tunicate Ecteinascidia turbin

NICE rejects PharmaMar’s ovarian cancer drug Yondelis

March 14, 2011
Sales and Marketing Cancer, NICE, PharmaMar, Trabectedin, Yondelis, ovarian cancer

NICE has rejected PharmaMar’s ovarian cancer drug in final draft guidance due to a lack of ‘robust’ data. Yondelis (trabectedin) …

News

NICE stands firm on Tarceva

March 11, 2011
Cancer, NICE, Roche, Tarceva, erlotinib

NICE has not recommended Roche’s lung cancer drug Tarceva because its effectiveness as a maintenance therapy remains unclear. NICE is …

News

NICE rejects Lucentis for diabetic oedema

March 4, 2011
Sales and Marketing Lucentis, NICE, Novartis, VEGF, Vascular Endothelial Growth Factor, diabetic oedema, raibizumab

NICE’s draft guidance has not recommended Lucentis for diabetic oedema after ‘faulty analysis’ from manufacturer Novartis was found not to …

News
Roche's Avastin (bevacizumab)

NICE yes for Votrient, no to Avastin

February 23, 2011
Sales and Marketing Cancer, GSK, GlaxoSmithKline, Kidney cancer, NICE, Roche, avastin, bevacizumab, breast cancer

NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient on the same day it gave a final negative decision to Roche’s …

News

Value-based pricing will not harm industry, says NICE chief

February 18, 2011
Sales and Marketing Health Select Committee, Health and Social Care Bill, NHS reform, NICE, Sir Andrew Dillon, value-based pricing

NICE’s chief executive Sir Andrew Dillon says he believes plans to introduce value-based pricing of medicines will not have a …

News

Vidaza patient access scheme sways NICE

February 17, 2011
Sales and Marketing Celgene, NICE, Vidaza

Celgene’s Vidaza has been recommended by NICE in final draft guidance issued today. Vidaza (azacitidine) is recommended as a treatment …

News

Early diagnosis key to UK cancer ambition

February 8, 2011
Cancer, NHS, NICE

A series of quality standards on cancer care is to be drawn up by NICE as part of a new …

Feature

Decision on osteoporosis drug Protelos unchanged, says NICE

January 27, 2011
Sales and Marketing NICE, Protelos, Servier, osteoporotic fractures, strontium ranelate

NICE has published updated final guidance on preventing osteoporotic fractures following a reconsideration of the use of Servier’s Protelos. The …

News

NICE decides to back Abilify in schizophrenia

January 27, 2011
Sales and Marketing Abilify, BMS, Bristol-Myers Squibb, NICE, Otsuka, aripiprazole, schizophrenia

NICE has changed its mind over Bristol-Myers Squibb’s and Otsuka Pharmaceuticals Abilify, deciding to recommend the drug as a schizophrenia …

News
ABPI

ABPI warns of postcode prescribing

January 21, 2011
Sales and Marketing ABPI, Cancer Drugs Fund, NICE, cancer drug prescribing, postcode prescribing

The ABPI has said the government’s forthcoming Cancer Drugs Fund could increase the problems of postcode prescribing. The UK industry …

News

Health Bill continues fast pace of NHS reform

January 20, 2011
Sales and Marketing GP consortia, NHS, NHS Commissioning Board, NHS reforms, NICE, QALY

The government has outlined its draft Health and Social Care Bill, making some minor concessions to critics but promising no …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026